Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8472154-allergan-my-glaucoma-von-miller/
"Growing up, I had challenges with my vision. I don't have glaucoma, but I know firsthand how it feels to deal with vision issues. Because of this, I'm dedicated to helping others who suffer from visual impairments and their caregivers," said
As a child, Miller suffered from vision problems. This made school a challenge for him and he struggled to maintain a positive self-image because of it. Miller finally took control of his vision after a visit to his eye doctor and gained back his confidence that led him to go on to play professional football. Because of this, and knowing firsthand the feeling of losing your sight to any degree, Miller is passionate about helping others take control of their visual impairments and is excited about the opportunity to spotlight the misunderstandings and impact of living with glaucoma by joining
"Following results from a survey of patients with glaucoma, which showed that there are many misperceptions about the disease, we launched the 'My Glaucoma' program in 2019 to amplify and highlight the seriousness of the disease, and encourage people on the frontlines and their caregivers to have meaningful conversations with their doctors," said
'My Glaucoma' includes an educational video featuring Miller, in which he discusses how vision loss has impacted him and why people need to take early action against their glaucoma. Additionally, Miller and
About the 'My Glaucoma' Campaign
The 'My Glaucoma' campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment regimen that fits their lifestyle. The resources available on www.MyGlaucoma.com are supported by a new survey of patients living with glaucoma and eye doctors, conducted in collaboration with Glaucoma Research Foundation (GRF), that found more than 75 percent of patients worry about vision loss because of the disease, but nearly half consider glaucoma to be only somewhat or not serious. In fact, research published by the
As a leader in eye care, Allergan sought to listen to the voices of patients with glaucoma and eye care professionals to put together meaningful resources that everyone living with glaucoma can benefit from. The interactive website www.MyGlaucoma.com offers access to videos that include perspectives from patients living with glaucoma and their caregivers, more information from the survey and patient resources, such as a conversation guide and facts about glaucoma diagnosis and treatment.
Glaucoma is one of the primary causes of irreversible vision loss and blindness. An estimated 70 million people globally are living with glaucoma. This progressive disease is characterized by elevated intraocular pressure (IOP). Uncontrolled, elevated IOP causes damage to the optic nerve and loss of vision. Reduction of elevated IOP is the only proven way to slow the progression of vision loss associated with glaucoma.
Current treatments to lower IOP include topical medications (eye drops), laser trabeculoplasty, minimally invasive glaucoma surgery and incisional surgery. Eye drop medications are the standard first-line treatment for open-angle glaucoma, the most common form, but low patient adherence to these medications is common – up to 80 percent of patients are not using topical medications as prescribed. Poor adherence to glaucoma medication could result in disease progression and vision loss. According to a study published by the
About Allergan Eye Care
As a leader in eye care,
Our commitment to the well-being of patients is also reflected in social responsibility.
With colleagues and commercial operations located in approximately 100 countries,
For more information, visit
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.